艾滋病毒耐药性对撒哈拉以南非洲地区与艾滋病毒/艾滋病相关的死亡率、新感染率及抗逆转录病毒治疗项目成本的影响
Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa.
作者信息
Phillips Andrew N, Stover John, Cambiano Valentina, Nakagawa Fumiyo, Jordan Michael R, Pillay Deenan, Doherty Meg, Revill Paul, Bertagnolio Silvia
机构信息
Institute for Global Health, University College London, United Kingdom.
Avenir Health, Glastonbury, Connecticut.
出版信息
J Infect Dis. 2017 May 1;215(9):1362-1365. doi: 10.1093/infdis/jix089.
Abstract
To inform the level of attention to be given by antiretroviral therapy (ART) programs to HIV drug resistance (HIVDR), we used an individual-level model to estimate its impact on future AIDS deaths, HIV incidence, and ART program costs in sub-Saharan Africa (SSA) for a range of program situations. We applied this to SSA through the Spectrum-Goals model. In a situation in which current levels of pretreatment HIVDR are over 10% (mean, 15%), 16% of AIDS deaths (890 000 deaths), 9% of new infections (450 000), and 8% ($6.5 billion) of ART program costs in SSA in 2016-2030 will be attributable to HIVDR.
摘要
为了告知抗逆转录病毒治疗（ART）项目对HIV耐药性（HIVDR）应给予的关注程度，我们使用了一个个体水平模型来估计其在一系列项目情况下对撒哈拉以南非洲（SSA）未来艾滋病死亡、HIV发病率和ART项目成本的影响。我们通过Spectrum-Goals模型将其应用于SSA。在治疗前HIVDR当前水平超过10%（平均为15%）的情况下，2016年至2030年SSA地区16%的艾滋病死亡（89万例死亡）、9%的新感染（45万例）以及8%（65亿美元）的ART项目成本将归因于HIVDR。
相似文献
1
Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa.艾滋病毒耐药性对撒哈拉以南非洲地区与艾滋病毒/艾滋病相关的死亡率、新感染率及抗逆转录病毒治疗项目成本的影响
J Infect Dis. 2017 May 1;215(9):1362-1365. doi: 10.1093/infdis/jix089.
2
Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.治疗前的 HIV 耐药性会增加撒哈拉以南非洲地区的治疗方案转换。
Clin Infect Dis. 2015 Dec 1;61(11):1749-58. doi: 10.1093/cid/civ656. Epub 2015 Aug 3.
3
Evaluation of treatment response, drug resistance and HIV-1 variability among adolescents on first- and second-line antiretroviral therapy: a study protocol for a prospective observational study in the centre region of Cameroon (EDCTP READY-study).对接受一线和二线抗逆转录病毒治疗的青少年的治疗反应、耐药性及HIV-1变异性的评估：喀麦隆中部地区一项前瞻性观察性研究的研究方案（EDCTP READY研究）
BMC Pediatr. 2019 Jul 5;19(1):226. doi: 10.1186/s12887-019-1599-z.
4
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.撒哈拉以南非洲地区抗逆转录病毒治疗推出后，抗逆转录病毒初治个体中的 HIV-1 耐药性：一项多中心观察性研究。
Lancet Infect Dis. 2011 Oct;11(10):750-9. doi: 10.1016/S1473-3099(11)70149-9. Epub 2011 Jul 27.
5
The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.评估撒哈拉以南非洲地区艾滋病毒耐药性检测的REVAMP试验：资源有限环境下临床试验设计的案例研究，以优化有效性和成本效益估计。
HIV Clin Trials. 2017 Jul;18(4):149-155. doi: 10.1080/15284336.2017.1349028. Epub 2017 Jul 18.
6
Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models.COVID-19 对撒哈拉以南非洲地区艾滋病毒规划造成的潜在影响：来自多个数学模型的结果。
Lancet HIV. 2020 Sep;7(9):e629-e640. doi: 10.1016/S2352-3018(20)30211-3. Epub 2020 Aug 6.
7
The association between HIV pretreatment drug resistance and virological outcomes in children and adults in sub-Saharan Africa: A systematic review and meta-analysis.撒哈拉以南非洲地区儿童和成人中 HIV 预处理耐药性与病毒学结局之间的关联：系统评价和荟萃分析。
PLoS One. 2024 Apr 16;19(4):e0300456. doi: 10.1371/journal.pone.0300456. eCollection 2024.
8
Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models.暴露前预防对撒哈拉以南非洲地区HIV-1耐药性的影响有限：数学模型比较
AIDS. 2013 Nov 28;27(18):2943-51. doi: 10.1097/01.aids.0000433237.63560.20.
9
Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.撒哈拉以南非洲地区成人和儿童一线抗逆转录病毒治疗持续病毒学失败后HIV-1耐药性的累积
J Antimicrob Chemother. 2016 Oct;71(10):2918-27. doi: 10.1093/jac/dkw218. Epub 2016 Jun 23.
10
Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa.低水平使用抗逆转录病毒疗法能够遏制撒哈拉以南非洲地区艾滋病流行的程度。
Lancet. 2000 Jun 17;355(9221):2095-100. doi: 10.1016/S0140-6736(00)02375-8.
引用本文的文献
1
HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018-2024.现代抗逆转录病毒药物时代的HIV-1耐药性趋势：2018 - 2024年
Open Forum Infect Dis. 2025 Aug 4;12(8):ofaf446. doi: 10.1093/ofid/ofaf446. eCollection 2025 Aug.
2
HIV-1 Drug Resistance in Children and Implications for Pediatric Treatment Strategies: A Systematic Review and Meta-analysis.儿童HIV-1耐药性及其对儿科治疗策略的影响：一项系统评价和荟萃分析。
Open Forum Infect Dis. 2025 Jun 26;12(7):ofaf378. doi: 10.1093/ofid/ofaf378. eCollection 2025 Jul.
3
Antimicrobial resistance with a focus on antibacterial, antifungal, antimalarial, and antiviral drugs resistance, its threat, global priority pathogens, prevention, and control strategies: a review.以抗菌、抗真菌、抗疟和抗病毒药物耐药性为重点的抗微生物药物耐药性、其威胁、全球重点病原体、预防和控制策略：综述
Ther Adv Infect Dis. 2025 May 23;12:20499361251340144. doi: 10.1177/20499361251340144. eCollection 2025 Jan-Dec.
4
Noncanonical HIV drug resistance mutations: need to close existing gaps.非典型HIV耐药性突变：需要填补现有差距。
AIDS. 2025 Jun 1;39(7):781-787. doi: 10.1097/QAD.0000000000004170. Epub 2025 Mar 17.
5
Pretreatment and acquired HIV drug resistance in Belize-results of nationally representative surveys, 2021-22.伯利兹的艾滋病病毒治疗前及获得性耐药情况——2021 - 2022年全国代表性调查结果
J Antimicrob Chemother. 2025 Jan 3;80(1):292-300. doi: 10.1093/jac/dkae408.
6
[Analysis of HIV-1 Subtypes and Transmitted Drug Resistance in Hospitalized Treatment-Native Patients With AIDS].[住院治疗的本地艾滋病患者中HIV-1亚型及传播耐药性分析]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2024 Sep 20;55(5):1295-1300. doi: 10.12182/20240960209.
7
Global, regional, and national prevalence of HIV-1 drug resistance in treatment-naive and treatment-experienced children and adolescents: a systematic review and meta-analysis.初治和经治儿童及青少年中HIV-1耐药性的全球、区域和国家流行率：一项系统评价和荟萃分析。
EClinicalMedicine. 2024 Oct 4;77:102859. doi: 10.1016/j.eclinm.2024.102859. eCollection 2024 Nov.
8
Population dynamics of HIV drug resistance during treatment scale-up in Uganda: a population-based longitudinal study.乌干达扩大治疗期间艾滋病毒耐药性的人群动态：一项基于人群的纵向研究。
medRxiv. 2024 Oct 9:2023.10.14.23297021. doi: 10.1101/2023.10.14.23297021.
9
MARVEL-minimising the emergence and dissemination of HIV-1 drug resistance in Portuguese-speaking African Countries (PALOP): low-cost portable NGS platform for HIV-1 surveillance in Africa.在葡萄牙语非洲国家（PALOP）减少 HIV-1 耐药性的出现和传播的 MARVEL 研究：用于非洲 HIV-1 监测的低成本便携式 NGS 平台。
BMC Infect Dis. 2024 Aug 29;24(1):884. doi: 10.1186/s12879-024-09803-1.
10
HIV-1 Drug Resistance Detected by Next-Generation Sequencing among ART-Naïve Individuals: A Systematic Review and Meta-Analysis.基于下一代测序的初治人群中 HIV-1 耐药性的检测：系统评价和荟萃分析。
Viruses. 2024 Feb 2;16(2):239. doi: 10.3390/v16020239.
本文引用的文献
1
What Is Required to End the AIDS Epidemic as a Public Health Threat by 2030? The Cost and Impact of the Fast-Track Approach.到2030年将艾滋病疫情作为公共卫生威胁终结需要什么？快速通道方法的成本与影响。
PLoS One. 2016 May 9;11(5):e0154893. doi: 10.1371/journal.pone.0154893. eCollection 2016.
2
Sharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillance.博茨瓦纳产前诊所中通过药物传播的艾滋病毒耐药率急剧上升，这表明有必要进行常规监测。
J Antimicrob Chemother. 2016 May;71(5):1361-6. doi: 10.1093/jac/dkv500. Epub 2016 Feb 29.
3
Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.在开始接受抗逆转录病毒药物治疗的抗逆转录病毒药物初治人群中，针对未来高水平传播的 HIV 耐药性的潜在应对措施的有效性和成本效益：建模研究和经济分析。
Lancet HIV. 2014 Nov;1(2):e85-93. doi: 10.1016/S2352-3018(14)70021-9. Epub 2014 Oct 14.
4
Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation.预测 HIV 耐药水平：扩大抗逆转录病毒治疗启动的诊断、保留和资格标准的潜在影响。
AIDS. 2014 Jan;28 Suppl 1:S15-23. doi: 10.1097/QAD.0000000000000082.
5
Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling study.扩大抗逆转录病毒治疗资格可避免的艾滋病感染抵消了传播耐药性的风险：一项建模研究。
AIDS. 2014 Jan 2;28(1):73-83. doi: 10.1097/01.aids.0000433239.01611.52.
6
HIV-1 genetic diversity and transmitted drug resistance mutations among patients from the North, Central and South regions of Angola.安哥拉北部、中部和南部地区患者的 HIV-1 遗传多样性和传播耐药性突变。
PLoS One. 2012;7(8):e42996. doi: 10.1371/journal.pone.0042996. Epub 2012 Aug 29.
7
Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis.资源有限环境下抗逆转录病毒治疗推出后治疗初治 HIV 感染者的抗逆转录病毒耐药全球趋势：一项全球协作研究和荟萃回归分析。
Lancet. 2012 Oct 6;380(9849):1250-8. doi: 10.1016/S0140-6736(12)61038-1. Epub 2012 Jul 23.
8
Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study.撒哈拉以南非洲地区一线抗反转录病毒治疗中预处理 HIV-1 耐药性对免疫、病毒学和耐药性结局的影响：一项多中心队列研究。
Lancet Infect Dis. 2012 Apr;12(4):307-17. doi: 10.1016/S1473-3099(11)70255-9. Epub 2011 Oct 27.
9
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.传播耐药性对初始联合抗逆转录病毒治疗 HIV 的病毒学和免疫学反应的影响（EuroCoord-CHAIN 联合项目）：一项欧洲多队列研究。
Lancet Infect Dis. 2011 May;11(5):363-71. doi: 10.1016/S1473-3099(11)70032-9. Epub 2011 Feb 25.
Zotero 插件